Chile looks at non-AUGE coverage:
This article was originally published in Clinica
Executive Summary
Chile has expressed general satisfaction at the results of an assessment of the quality of primary and secondary care services not covered by the AUGE "explicit healthcare guarantees" programme, but acknowledges that some areas will need improving. Low rates of cervical smear (Pap) screening and apparent deficiencies in the care of diabetes and hypertension are a source of concern, said the government's subsecretary of healthcare networks, Ricardo Fabrega. In addition, progress in providing hip replacement surgery (in age groups exempt from AUGE) had "slightly levelled out", he said. Despite this, "the results of this study refute suggestions that Plan AUGE would result in deficiencies in areas of care that are not yet included in the programme," said Mr Fabrega.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.